Clinical Trial Update: Study Of Diabetic Nephropathy With Atrasentan [Phase 3]

View source ↗

Summary

Phase 3 trial of atrasentan for diabetic nephropathy was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: AbbVie | Conditions: Diabetic Nephropathy | Phase 3 | Status: TERMINATED | Results posted: 2019-04-24